Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of Myocet + Trastuzumab + Paclitaxel vs Trastuzumab + Paclitaxel in HER2-positive Metastatic Breast Cancer
2005-006109-19Phase 3Completed
- Sponsor
- Sopherion Therapeutics
- Start
- Apr 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of doxorubicin in HER2-enriched breast cancer (HER2+) (2 arms), sponsored by Sopherion Therapeutics. Primary endpoints: Overall survival and Cardiac safety. Started Apr 2006; status: completed.
02
Drugs
doxorubicin
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2005-006109-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006109-19.